Figure 1.

Ex vivo expression of NKG2A is highest on CD8 αβ T cells infiltrating colorectal tumors, regardless of MSS/MSI status. (a) Distribution of viable NKG2A⁺ lymphoid cells among αβ T cells (CD3⁺TCRαβ⁺ cells), γδ T cells (CD3⁺TCRγδ⁺ cells), and NK cells (CD3⁻CD56⁺) in 20 colorectal tumors; Friedman’s test, followed by Dunn’s multiple comparisons test. (b) Representative density plots of NKG2A expression on CD3⁺CD8⁺ T cells in healthy tissues (1.1 and 6.6%, top) and tumor tissues (16.7 and 9.4%, bottom), respectively from C161 and C170 patients. (c) Paired frequencies of NKG2A⁺ cells among CD8 T cells in paired tumor and normal tissues (n = 29); Wilcoxon paired t test. (d) Frequencies of NKG2A⁺ cells among CD8⁺ TILs according to MSS/MSI status (n = 35); Mann–Whitney test.